Back

Association between treatment and MACE during follow-up in patients with Takotsubo syndrome

14 March 2025 (17:20 - 18:20)
Organised by: Logo
Congress Presentation Part of: Improving outcomes in acute heart failure Clinical ACVC Premium Access ESC Acute CardioVascular Care 2025 Association for Acute CardioVascular Care (ACVC)

About the speaker

Photo
Doctor Paula Marin Andreu

University Hospital of Virgen Macarena, Seville (Spain)

8 More presentations in this session

Presentation thumbnail
Clinical determinants and long-term survival in heart failure with supra-normal ejection fraction. Insights from LECRA-HF registry.
Doctor K. Stepien (Krakow, PL)
Abstract Slides
Presentation thumbnail
Early predictors of in-hospital mortality in patients with acute heart failure. A general hospital experience
Doctor G. Aletras (Heraklion, GR)
Abstract Slides
Presentation thumbnail
Predictors of mortality in heart failure patients with reduced ejection fraction: neutrophil-to-lymphocyte ratio, platelets-to-lymphocyte ratio, neutrophil- percentage-to-albumin-ratio
Doctor J. Stevic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Genetic insights into cardiomyopathy: familial and histologic features of transplant-dependent failing hearts in hcmp
Doctor K. Kim (Incheon, KR)
Abstract Slides
Presentation thumbnail
Additional benefits ofSGLT2i therapy in patients with acute decompensated heart failure and central sleep apnea.
Assistant Professor P. Kalaydzhiev (Sofia, BG)
Abstract Slides

Access the full session

Session thumbnail
Improving outcomes in acute heart failure

The Event

Event poster

ESC Acute CardioVascular Care 2025

14 March 2025 17:20 CET
You may be interested in
thumbnail
Congress Presentation
Current challenges in pharmacological treatment of Takotsubo syndrome: is there a long way to go?
15 March 2025
thumbnail
Congress Presentation
Insights into the reporting of major adverse cardiovascular events in coronary artery disease trials
30 August 2024
thumbnail
Congress Presentation
The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe
28 August 2022
thumbnail
Congress Presentation
In-hospital dynamics of trimethylamine N-oxide (TMAO) predicts major adverse cardiovascular events in patients with acute myocardial infarction
25 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources